Literature DB >> 30137324

A severe mouse model of spinal muscular atrophy develops early systemic inflammation.

Bo Wan1,2, Pengchao Feng1,2, Zeyuan Guan1,2, Lei Sheng1,2, Zhiyong Liu3,4, Yimin Hua1,2.   

Abstract

Spinal muscular atrophy (SMA) is a fatal genetic disease, mainly affecting children. A number of recent studies show, aside from lower motor neuron degeneration and atrophy of skeletal muscles, widespread defects present in the central nervous system (CNS) and peripheral non-neuronal cell types of SMA patients and mouse models, particularly of severe forms. However, molecular mechanisms underlying the multi-organ manifestations of SMA were hardly understood. Here, using histology, flow cytometry and gene expression analysis in both messenger RNA and protein levels in various tissues, we found that a severe SMA mouse model develops systemic inflammation in early symptomatic stages. SMA mice had an enhanced intestinal permeability, resulting in microbial invasion into the circulatory system. Expression of proinflammatory cytokines was increased in all tissues and the acute phase response in the liver was activated. Systemic inflammation further mobilized glucocorticoid signaling and in turn led to dysregulation of a large set of genes, including robust upregulation of FAM107A in the spinal cord, increased expression of which has been implicated in neurodegeneration. Moreover, we show that lipopolysaccharide challenge markedly suppressed survival of motor neuron 2 exon 7 splicing in all examined peripheral and CNS tissues, resulting in global survival of motor neuron level reduction. Therefore, we identified a novel pathological mechanism in a severe SMA mouse model, which affects phenotypic severity through multiple paths and should contribute to progression of broad neuronal and non-neuronal defects.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30137324     DOI: 10.1093/hmg/ddy300

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  11 in total

Review 1.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

2.  Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.

Authors:  Laura Bianchi; Maria Sframeli; Lorenza Vantaggiato; Gian Luca Vita; Annamaria Ciranni; Francesca Polito; Rosaria Oteri; Eloisa Gitto; Fabrizio Di Giuseppe; Stefania Angelucci; Antonio Versaci; Sonia Messina; Giuseppe Vita; Luca Bini; M'hammed Aguennouz
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

3.  SMN deficiency causes pain hypersensitivity in a mild SMA mouse model through enhancing excitability of nociceptive dorsal root ganglion neurons.

Authors:  Ruobing Qu; Fuping Yao; Xiaomin Zhang; Yuan Gao; Tong Liu; Yimin Hua
Journal:  Sci Rep       Date:  2019-04-24       Impact factor: 4.379

4.  Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA.

Authors:  Irving Donadon; Erica Bussani; Federico Riccardi; Danilo Licastro; Giulia Romano; Giulia Pianigiani; Mirko Pinotti; Pavlina Konstantinova; Melvin Evers; Shuo Lin; Markus A Rüegg; Franco Pagani
Journal:  Nucleic Acids Res       Date:  2019-08-22       Impact factor: 16.971

5.  Survival motor neuron protein deficiency alters microglia reactivity.

Authors:  Guzal Khayrullina; Zaida A Alipio-Gloria; Marc-Olivier Deguise; Sabrina Gagnon; Lucia Chehade; Matthew Stinson; Natalya Belous; Elizabeth M Bergman; Fritz W Lischka; Jeremy Rotty; Clifton L Dalgard; Rashmi Kothary; Kristen A Johnson; Barrington G Burnett
Journal:  Glia       Date:  2022-04-04       Impact factor: 8.073

6.  Suppression of the necroptotic cell death pathways improves survival in Smn 2B/- mice.

Authors:  Lucia Chehade; Marc-Olivier Deguise; Yves De Repentigny; Rebecca Yaworski; Ariane Beauvais; Sabrina Gagnon; Niko Hensel; Rashmi Kothary
Journal:  Front Cell Neurosci       Date:  2022-08-03       Impact factor: 6.147

Review 7.  History of development of the life-saving drug "Nusinersen" in spinal muscular atrophy.

Authors:  Jiaying Qiu; Liucheng Wu; Ruobing Qu; Tao Jiang; Jialin Bai; Lei Sheng; Pengchao Feng; Junjie Sun
Journal:  Front Cell Neurosci       Date:  2022-08-12       Impact factor: 6.147

8.  Single-cell RNA sequencing reveals dysregulation of spinal cord cell types in a severe spinal muscular atrophy mouse model.

Authors:  Junjie Sun; Jiaying Qiu; Qiongxia Yang; Qianqian Ju; Ruobing Qu; Xu Wang; Liucheng Wu; Lingyan Xing
Journal:  PLoS Genet       Date:  2022-09-08       Impact factor: 6.020

9.  Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy.

Authors:  Anna A L Motyl; Kiterie M E Faller; Ewout J N Groen; Rachel A Kline; Samantha L Eaton; Leire M Ledahawsky; Helena Chaytow; Douglas J Lamont; Thomas M Wishart; Yu-Ting Huang; Thomas H Gillingwater
Journal:  Hum Mol Genet       Date:  2020-09-29       Impact factor: 6.150

10.  Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.

Authors:  Giammarco Milella; Alessandro Introna; Eustachio D'Errico; Angela Fraddosio; Gaspare Scaglione; Antonella Morea; Maria Ucci; Maddalena Ruggieri; Mariangela Mastrapasqua; Marisa Megna; Filomena Puntillo; Isabella Laura Simone
Journal:  Clin Drug Investig       Date:  2021-08-13       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.